FY2025 EPS Forecast for Janux Therapeutics Raised by Analyst

Janux Therapeutics, Inc. (NASDAQ:JANX) – Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Janux Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.92) for the year, up from their previous forecast of ($2.21). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q4 2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.70) EPS, FY2027 earnings at ($2.86) EPS, FY2028 earnings at ($1.06) EPS and FY2029 earnings at $1.40 EPS.

Several other equities analysts have also recently issued reports on the stock. Truist Financial assumed coverage on shares of Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price target on the stock. Guggenheim started coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 target price on the stock. Wedbush restated an “outperform” rating and set a $76.00 target price on shares of Janux Therapeutics in a report on Friday, November 7th. Piper Sandler assumed coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $42.00 price objective on the stock. Finally, Barclays boosted their price target on Janux Therapeutics from $47.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $79.17.

Janux Therapeutics Trading Up 4.6%

Shares of NASDAQ JANX opened at $28.87 on Wednesday. Janux Therapeutics has a 12 month low of $21.73 and a 12 month high of $71.71. The firm has a market capitalization of $1.74 billion, a PE ratio of -17.18 and a beta of 2.83. The firm has a fifty day simple moving average of $25.32 and a two-hundred day simple moving average of $25.15.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $30.06, for a total transaction of $500,949.90. Following the transaction, the insider owned 82,139 shares of the company’s stock, valued at $2,469,098.34. The trade was a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds have recently modified their holdings of the stock. Fox Run Management L.L.C. purchased a new position in Janux Therapeutics during the third quarter valued at $594,000. TD Asset Management Inc increased its holdings in shares of Janux Therapeutics by 41.5% in the third quarter. TD Asset Management Inc now owns 92,302 shares of the company’s stock worth $2,256,000 after purchasing an additional 27,066 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of Janux Therapeutics in the third quarter worth about $569,000. Readystate Asset Management LP boosted its stake in Janux Therapeutics by 38.0% during the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock valued at $23,472,000 after buying an additional 264,423 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Janux Therapeutics during the 3rd quarter valued at approximately $378,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.